FDA approves Lilly's oral SERD combo for second-line breast cancer therapy

The FDA has approved a new combination regimen from Eli Lilly for certain breast cancer patients. This regimen includes Lilly's oral selective estrogen receptor degrader (SERD) drug Inluriyo. According to Endpoints News, the approval is for second-line breast cancer therapy.

The approval is for patients with metastatic breast cancer.

There is no additional information in the reports to provide further details on the regimen or its usage.

Brief written by urgent.news from Endpoints News, STAT News — 2 reports on this story. Machine-written — may contain errors; check the original before relying on it.